2026-04-17T02:54:48Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/101902025-10-24T10:40:07Zcom_2072_378070com_2072_378040col_2072_378092

00925njm 22002777a 4500 dc Puyana Ortiz, Juan David author Garcés Rodríguez, Andrea Carolina author Martínez-Campreciós, Joan author Saborit Braceros, Núria author Rodrigo Pendás, José Ángel author García Salgado, Guadalupe author Broto Cortés, Claudia author Serre Delcor, Nuria author Salvador Velez, Fernando M author Torrecilla Martínez, Irene author Zules Oña, Ricardo Gabriel author Tórtola Fernández, María Teresa author Aznar, María Luisa author Espinosa-Pereiro, Juan author Treviño Maruri, Begoña author Pou Ciruelo, Diana author Bosch-Nicolau, Pau author Sánchez Montalvá, Adrián author Molina Romero, Israel author Oliveira Souto, Inés author 2023-08-30T11:54:54Z 2023-08-30T11:54:54Z 2023-07-19 Latent tuberculosis infection; Toxicity; Tuberculosis screening Infecció tuberculosa latent; Toxicitat; Cribratge de tuberculosi Infección tuberculosa latente; Toxicidad; Cribado de tuberculosis The screening and treatment of latent tuberculosis infection (LTBI) in countries with a low incidence of TB is a key strategy for the elimination of tuberculosis (TB). However, treatment can result in adverse events (AEs) and have poor adherence. This study aimed to describe treatment outcomes and AEs for LTBI patients at two departments in Vall d'Hebron University Hospital in Barcelona, Spain. A retrospective study was conducted on all persons treated for LTBI between January 2018 and December 2020. Variables collected included demographics, the reason for LTBI screening and treatment initiation, AEs related to treatment, and treatment outcome. Out of 261 persons who initiated LTBI treatment, 145 (55.6%) were men, with a median age of 42.1 years. The indications for LTBI screening were household contact of a TB case in 96 (36.8%) persons, immunosuppressive treatment in 84 (32.2%), and recently arrived migrants from a country with high TB incidence in 81 (31.0%). Sixty-three (24.1%) persons presented at least one AE during treatment, and seven (2.7%) required definitive discontinuation of treatment. In the multivariate analysis, AE development was more frequent in those who started LTBI treatment due to immunosuppression. Overall, 226 (86.6%) completed treatment successfully. We concluded that LTBI screening and treatment groups had different risks for adverse events and treatment outcomes. Persons receiving immunosuppressive treatment were at higher risk of developing AEs, and recently arrived immigrants from countries with a high incidence of TB had greater LTFU. A person-centered adherence and AE management plan is recommended. A.M.L. was supported by a postdoctoral grant “Juan Rodés” (JE21/00027) from the Instituto de Salud Carlos through the Ministry of Economy and Competitiveness, Spain. http://hdl.handle.net/11351/10190 Medicaments antituberculosos - Efectes secundaris Tuberculosi - Tractament DISEASES::Bacterial Infections and Mycoses::Bacterial Infections::Gram-Positive Bacterial Infections::Actinomycetales Infections::Mycobacterium Infections::Tuberculosis::Latent Tuberculosis CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Anti-Bacterial Agents::Antitubercular Agents Other subheadings::Other subheadings::Other subheadings::/adverse effects ENFERMEDADES::infecciones bacterianas y micosis::infecciones bacterianas::infecciones por bacterias grampositivas::infecciones por Actinomycetales::micobacteriosis::tuberculosis::tuberculosis latente COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antibacterianos::antituberculosos Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos Adherence and Toxicity during the Treatment of Latent Tuberculous Infection in a Referral Center in Spain